The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | Multi-omics studies to understand the progression from premalignant states to WM
Simone Ferrero, MD, University of Torino and Hospital “Città della Salute e della Scienza di Torino”, Torino, Italy, discusses the potential of multi-omics in understanding the progression from non-tumoral premalignant states to overt Waldenström’s macroglobulinemia (WM). He introduces research examining gene mutations, RNA expression, and the role of non-malignant cell mutations in inflammation and disease progression. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant: Janssen, EUSA Pharma, Abbvie and Sandoz; Advisory board: Janssen, EUSA Pharma, Recordati, Incyte, Roche, Astra Zeneca and Italfarmaco; Speaker’s honoraria: Janssen, EUSA Pharma, Recordati, Lilly, Beigene, Gilead and Gentili ; Research funding: Gilead, Beigene and Morphosys.
